Cutler Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-158,363
| Closed | -$10.1M | – | 126 |
|
|
2023
Q2 | $10.1M | Sell |
158,363
-4,296
| -3% | -$288K | 1.53% | 27 |
|
|
2023
Q1 | $11.3M | Buy |
162,659
+840
| +0.5% | +$59.2K | 1.75% | 24 |
|
|
2022
Q4 | $11.6M | Sell |
161,819
-5,810
| -3% | -$438K | 1.78% | 24 |
|
|
2022
Q3 | $11.9M | Sell |
167,629
-497
| -0.3% | -$36.1K | 1.98% | 17 |
|
|
2022
Q2 | $13M | Buy |
168,126
+1,849
| +1% | +$141K | 2.05% | 15 |
|
|
2022
Q1 | $12.1M | Buy |
166,277
+4,949
| +3% | +$332K | 1.68% | 21 |
|
|
2021
Q4 | $10.1M | Buy |
161,328
+2,600
| +2% | +$153K | 1.51% | 27 |
|
|
2021
Q3 | $9.39M | Buy |
158,728
+1,101
| +0.7% | +$72.5K | 1.48% | 29 |
|
|
2021
Q2 | $10.5M | Buy |
157,627
+625
| +0.4% | +$40.8K | 1.65% | 20 |
|
|
2021
Q1 | $9.91M | Buy |
157,002
+1,081
| +0.7% | +$67.3K | 1.72% | 21 |
|
|
2020
Q4 | $9.67M | Sell |
155,921
-483
| -0.3% | -$29.7K | 1.77% | 19 |
|
|
2020
Q3 | $9.43M | Buy |
156,404
+390
| +0.2% | +$23.5K | 1.83% | 19 |
|
|
2020
Q2 | $9.17M | Sell |
156,014
-2,017
| -1% | -$121K | 1.95% | 19 |
|
|
2020
Q1 | $8.81M | Sell |
158,031
-803
| -0.5% | -$49.1K | 2.13% | 19 |
|
|
2019
Q4 | $10.2M | Sell |
158,834
-24,601
| -13% | -$1.41M | 2.04% | 19 |
|
|
2019
Q3 | $9.3M | Buy |
183,435
+37,150
| +25% | +$1.75M | 1.79% | 25 |
|
|
2019
Q2 | $6.63M | Sell |
146,285
-591
| -0.4% | -$27.5K | 1.27% | 38 |
|
|
2019
Q1 | $7.01M | Buy |
146,876
+3,265
| +2% | +$163K | 1.37% | 37 |
|
|
2018
Q4 | $7.46M | Sell |
143,611
-3,820
| -3% | -$205K | 1.61% | 31 |
|
|
2018
Q3 | $9.15M | Buy |
147,431
+1,252
| +0.9% | +$74.3K | 1.71% | 26 |
|
|
2018
Q2 | $8.09M | Sell |
146,179
-1,947
| -1% | -$105K | 1.59% | 26 |
|
|
2018
Q1 | $9.37M | Buy |
148,126
+382
| +0.3% | +$24.6K | 1.83% | 24 |
|
|
2017
Q4 | $9.05M | Buy |
147,744
+1,363
| +0.9% | +$85.3K | 1.75% | 26 |
|
|
2017
Q3 | $9.33M | Buy |
146,381
+3,062
| +2% | +$179K | 2.18% | 18 |
|
|
2017
Q2 | $7.99M | Buy |
143,319
+1,960
| +1% | +$107K | 1.99% | 23 |
|
|
2017
Q1 | $7.69M | Buy |
141,359
+17,411
| +14% | +$955K | 1.79% | 25 |
|
|
2016
Q4 | $7.24M | Buy |
123,948
+439
| +0.4% | +$24K | 1.86% | 23 |
|
|
2016
Q3 | $6.66M | Buy |
123,509
+1,139
| +0.9% | +$73.2K | 1.8% | 24 |
|
|
2016
Q2 | $9M | Buy |
122,370
+2,792
| +2% | +$197K | 2.51% | 9 |
|
|
2016
Q1 | $7.64M | Sell |
119,578
-6,662
| -5% | -$420K | 2.34% | 11 |
|
|
2015
Q4 | $8.68M | Sell |
126,240
-443
| -0.3% | -$29.3K | 2.96% | 7 |
|
|
2015
Q3 | $7.5M | Buy |
126,683
+24
| +0% | +$1.52K | 2.68% | 8 |
|
|
2015
Q2 | $8.43M | Sell |
126,659
-21
| -0% | -$1.38K | 2.75% | 8 |
|
|
2015
Q1 | $8.17M | Sell |
126,680
-123
| -0.1% | -$7.7K | 2.63% | 9 |
|
|
2014
Q4 | $7.49M | Sell |
126,803
-479
| -0.4% | -$27K | 2.46% | 8 |
|
|
2014
Q3 | $6.51M | Sell |
127,282
-663
| -0.5% | -$33.1K | 2.22% | 13 |
|
|
2014
Q2 | $6.21M | Buy |
127,945
+5,445
| +4% | +$268K | 2.1% | 16 |
|
|
2014
Q1 | $6.36M | Buy |
122,500
+6,317
| +5% | +$336K | 2.25% | 12 |
|
|
2013
Q4 | $6.17M | Sell |
116,183
-487
| -0.4% | -$24.8K | 2.24% | 9 |
|
|
2013
Q3 | $5.4M | Sell |
116,670
-10
| -0% | -$439 | 2.1% | 17 |
|
|
2013
Q2 | $5.21M | Buy |
+116,680
| New | +$5.07M | 2.13% | 13 |
|
Other funds holding BMY
Cutler Investment Counsel's BMY Position: Q3 2023 in Review
Cutler Investment Counsel sold out of Bristol-Myers Squibb (BMY) in Q3 2023, closing a stake of 158,363 shares — an estimated $10.1M sold.
Cutler Investment Counsel first reported a position in BMY in Q2 2013 and held it in 41 quarters. The position peaked at $13M in Q2 2022. 2,388 funds tracked by Wall St. Rank hold BMY as of Q3 2023.
- Cutler Investment Counsel reported no remaining Bristol-Myers Squibb position as of Q3 2023 after selling out during the quarter.
- Cutler Investment Counsel sold 158,363 Bristol-Myers Squibb shares in Q3 2023, an estimated $10.1M.
- Cutler Investment Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 41 quarters.
- Cutler Investment Counsel's Bristol-Myers Squibb position peaked at $13M in Q2 2022.
- 2,388 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2023.
Based on Cutler Investment Counsel's 13F filing for Q3 2023, filed 25 Oct 2023.